Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
- This was a positive study in terms of progression-free survival. The progression-free survival was about 4 months better in the panobinostat arm.
- There were significantly more grade 3 toxicities, such as diarrhea, thrombocytopenia and fatigue, in the panobinostat arm.
- There is no signal in terms of better overall survival.